Legal
Refine Search
Biotechnology
India’s Sun Pharma has been blocked in its efforts to launch its JAK inhibitor Leqselvi (deuruxolitinib) in the USA. 6 November 2024
article
The European Union's antitrust enforcer hit Israeli drugmaker Teva Pharmaceutical Industries (NYSE: TEVA) with a 463 million-euro ($502 million) fine Thursday for launching a smear campaign against a rival multiple sclerosis drug and misusing the patent system to thwart the competitor's attempt to entering the market. 31 October 2024
Biotechnology
UK pharma major GSK has sued USA-based Moderna this week, accusing the latter of violating patents protecting GSK’s COVID-19 vaccine. 16 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
GSK has reached a settlement with 10 plaintiff firms, resolving 93% of the Zantac (ranitidine) product liability cases it faced in state courts across the USA. 10 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Generics
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
Pharmaceutical
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Biotechnology
Bristol Myers Squibb has scored a major legal victory as a judge in New York dismissed a $6.4 billion lawsuit related to its acquisition of cancer company Celgene. 5 October 2024
Pharmaceutical
The US Department of Health and Human Services (HHS) has released final guidance for the second cycle of Medicare drug price negotiations. 3 October 2024
Pharmaceutical
Texas-based Cassava Sciences was trading 13% lower in Friday’s pre-market trading. 27 September 2024
Pharmaceutical
The Pharmaceutical Research and Manufacturers of America (PhRMA) is continuing its legal challenge against the US government’s drug pricing reforms. 24 September 2024
Pharmaceutical
On Friday, the USA’s Federal Trade Commission (FTC) brought action against the three largest prescription drug benefit managers (PBMs) - Caremark Rx, Express Scripts (ESI), and OptumRx 23 September 2024
Pharmaceutical
In a lawsuit filed in federal court in Missouri, USA, Health insurer Cigna (NYSE: CI) and its pharmacy benefit manager (PBM) Express Scripts demanded that the Federal Trade Commission (FTC) retract its July 2024 report. 18 September 2024
Generics
Several pharma companies that had moved the Delhi High Court against the government’s recent notification banning 156 fixed-dose combination (FDC) drugs have got a breather. 10 September 2024
Generics
Glenmark Pharmaceuticals has agreed to pay $25 million, based on its ability to pay, to resolve its alleged liability under the False Claims Act for conspiring to fix the price of a generic drug, the US Department of Justice announced. 5 September 2024
Generics
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Biosimilars
Regeneron Pharmaceuticals has filed a lawsuit against Sandoz, alleging that its biosimilar to Eylea (aflibercept) infringes certain patents. 29 August 2024
Pharmaceutical
Ireland-headquartered Avadel Pharmaceuticals has updated on litigation with USA-based Jazz Pharmaceuticals. 29 August 2024
Pharmaceutical
Liquidia Corporation announced Thursday that it has filed litigation in the US District Court of the District of Columbia (Case No. 1:24-cv-02428) that challenges the recent decision by the US Food and Drug Administration (FDA) to grant three-year new clinical investigation (NCI) exclusivity to Tyvaso (treprostinil) DPI.9.6. 23 August 2024
Pharmaceutical
Swiss customs seized over 1,000 shipments of illegally imported therapeutic products last year, says Swissmedic, the body responsible for the authorisation and supervision of therapeutic products in Switzerland. 8 March 2017
Generics
Indian drugmaker Zydus Cadila has announced that it has finalized an agreement with the USA’s Supernus Pharmaceuticals to settle all outstanding patent litigation related to Trokendi XR (topiramate) extended-release capsules. 7 March 2017
Biosimilars
On Friday morning, a judgment was handed down in the hard-fought litigation between Japan’s Fujifilm Kyowa Kirin Biologics (FKB) and the USA’s AbbVie. 4 March 2017
Generics
The UK’s Competition and Markets Authority (CMA) today alleged that Concordia and Actavis UK signed illegal agreements which enabled high prices for a life-saving drug to be prolonged. 3 March 2017
Pharmaceutical
Canadian specialty pharmaceutical company Valeant Pharmaceuticals has issued a correction regarding a misleading news report. 2 March 2017
Pharmaceutical
US Senators Cory Booker (Democrat, New Jersey), Bernie Sanders (Independent, Vermont) and Bob Casey (Dem, Pennsylvania) introduced legislation Tuesday to lower the skyrocketing cost of prescription drugs by allowing Americans to import safe, low-cost medicine from Canada. 1 March 2017
Pharmaceutical
Following a public comment period, the US Federal Trade Commission has approved a final order settling charges that Boehringer Ingelheim’s $13.53 billion asset swap with Paris, France-based Sanofi would likely be anticompetitive. 27 February 2017
Generics
Pernix Therapeutics has received a favorable patent infringement ruling against Actavis Laboratories regarding a proposed generic version of opioid pain treatment Zohydro ER (hydrocodone bitartrate). 23 February 2017
Biosimilars
An industry trade group representing manufacturers of generic and biosimilar products has urged the US Supreme Court not to grant biotech firms an extra six months of patent exclusivity. 23 February 2017
Pharmaceutical
Debiopharm International has filed an appeal before the Supreme Court of Japan against the decision from the IP High Court (a special branch of the Tokyo High Court),. 23 February 2017
Biosimilars
Biocad and R-farm, the exclusive distributor for Swiss pharma giant Roche, continue their legal battles in Russia regarding the sale of Roche’s blockbuster cancer drug Herceptin (trastuzumab) and a biosimilar produced by Biocad. 21 February 2017
Generics
New challenges have been filed on patents for HIV drugs in India and Argentina by non-profit groups. 14 February 2017
Biotechnology
The Court of Appeals for the Federal Circuit has stayed (suspended) the permanent injunction for Praluent (alirocumab) Injection granted last month in a patent infringement dispute with US biotech Amgen pending an appeal. 9 February 2017
Pharmaceutical
The US Federal Trade Commission filed a complaint in federal district court charging Shire ViroPharma Inc with violating the antitrust laws by abusing government processes to delay generic competition to its branded prescription drug, Vancocin (vancomycin capsules. 8 February 2017
Pharmaceutical
Kitov Pharmaceuticals has announced that the Israeli Securities Authority has begun a formal investigation into the company’s public disclosures around its lead drug candidate, KIT-302. 7 February 2017
Pharmaceutical
Pernix Therapeutics has lost out in its arbitration dispute with UK pharma major GlaxoSmithKline. 4 February 2017
Pharmaceutical
The Japan IP High Court has confirmed the decisions of the Japan Patent Office and ruled against domestic firm Sawai in the invalidation trials initiated by Sawai regarding vitamin regimen patents for Alimta (pemetrexed for injection). 2 February 2017
Generics
Mylan might have had some share-boosting news with a court victory over a rival on Tuesday, but the shadow of a Federal Trade Commission (FTC) investigation continues to hang over the Netherlands-incorporated company. 31 January 2017
Generics
The US District Court for the District of Delaware issued a decision finding all asserted claims of four Orange Book-listed patents relating to the top-selling multiple sclerosis drug Copaxone (glatiramer acetate) 40 mg/mL invalid based on obviousness, according to Netherlands-incorporated Mylan. 31 January 2017
Pharmaceutical
As of now, collaborations between healthcare professionals and pharma in Spain are to be published individually, following an update to Code of Good Practice on the pharmaceutical industry. 30 January 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze